Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial

被引：0
|
作者：
Edwards, Christopher J. [1 ]
Aelion, Jacob A. [2 ]
Adebajo, Adewale O. [3 ]
Kivitz, Alan [4 ]
Bird, Paul [5 ]
Hu, ChiaChi [6 ]
Stevens, Randall M. [6 ]
Wells, Alvin [7 ]
机构：
[1] Southampton Univ Hosp, Southampton, Hants, England
[2] West Tennessee Res Inst, Jackson, TN USA
[3] Univ Sheffield, Sheffield, S Yorkshire, England
[4] Altoona Arthrit & Osteoporosis Ctr, Duncansville, PA USA
[5] Combined Rheumatol Practice, Kogarah, NSW, Australia
[6] Celgene Corp, Warren, NJ USA
[7] Rheumatol & Immunotherapy Ctr, Franklin, WI USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1572
引用
收藏
页码：S694 / S695
页数：2
相关论文
共 50 条
  • [1] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PALACE 4 PHASE 3, RANDOMIZED, CONTROLLED TRIAL
    Edwards, C.
    Wells, A.
    Adebajo, A.
    Kivitz, A.
    Bird, P.
    Shah, K.
    Hu, C.
    Stevens, R. M.
    Aelion, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 735 - 735
  • [2] Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials
    Gladman, Dafna D.
    Mease, Philip J.
    Kavanaugh, Arthur
    Adebajo, Adewale O.
    Gomez-Reino, Juan J.
    Wollenhaupt, Juergen
    Cutolo, Maurizio
    Schett, Georg
    Lespessailles, Eric
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher J.
    Birbara, Charles A.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S347 - S347
  • [3] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials
    Gladman, Dafna
    Mease, Phillip
    Kavanaugh, Arthur
    Adebajo, Adewale
    Gomez-Reino, Juan
    Wollenhaupt, Juergen
    Cutolo, Maurizio
    Schett, Georg
    Lespessailles, Eric
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall
    Edwards, Christopher
    Birbara, Charles
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1449 - 1449
  • [4] LONG-TERM (52-WEEK) RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS
    Kavanaugh, A.
    Mease, P. J.
    Adebajo, A. O.
    Wollenhaupt, J.
    Hu, C.
    Shah, K.
    Stevens, R. M.
    Gomez-Reino, J. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 163 - 163
  • [5] Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2)
    Cutolo, Maurizio
    Myerson, Gary E.
    Fleischmann, Roy M.
    Liote, Frederic
    Diaz-Gonzalez, Federico
    Van den Bosch, Filip
    Marzo-Ortega, Helena
    Feist, Eugen
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Poder, Airi
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S346 - S347
  • [6] Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)
    Kavanaugh, A.
    Mease, P.
    Adebajo, A.
    Wollenhaupt, J.
    Hu, A.
    Shah, K.
    Stevens, R.
    Gomez-Reino, J.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 131 - 131
  • [7] LONG-TERM 52-WEEK RESULTS OF PALACE 1, A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS
    Adebajo, Adewale O.
    Kavanaugh, Arthur
    Mease, Philip J.
    Wollenhaupt, Juergen
    Hu, ChiaChi
    Shah, Kamal
    Stevens, Randall M.
    Gomez-Reino, Juan J.
    [J]. RHEUMATOLOGY, 2014, 53 : 141 - 141
  • [8] Long-term 52-week results of PALACE 1, a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase inhibitor, in patients with psoriatic arthritis
    Adebajo, A.
    Gomez-Reino, J.
    Mease, P.
    Wollenhaupt, J.
    Hu, C. C.
    Shah, K.
    Stevens, R.
    Kavanaugh, A.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 12 - 12
  • [9] Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: Pooled results from three phase 3, randomized, controlled trials
    Gladman, Dafna
    Kavanaugh, Arthur
    Adebajo, Adewale
    Gomez-Reino, Juan
    Wollenhaupt, Juergen
    Cutolo, Maurizio
    Schett, Georg
    Lespessailles, Eric
    McIlraith, Melissa
    Hu, ChiaChi
    Edwards, Christopher
    Birbara, Charles
    Mease, Philip
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S32 - S32
  • [10] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE 3, RANDOMIZED, CONTROLLED TRIALS
    Gladman, D.
    Kavanaugh, A.
    Adebajo, A.
    Gomez-Reino, J.
    Wollenhaupt, J.
    Cutolo, M.
    Schett, G.
    Lespessailles, E.
    McIlraith, M.
    Hu, C.
    Edwards, C.
    Birbara, C.
    Mease, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 133 - 134
12345